Subscribe To
Royalty pharma agrees to acquire royalty interest in olpasiran from arrowhead for $250 million and future milestones
olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arr...
November 9, 2022, 1:49 pm
Amgen (amgn) olpasiran lowers lipoprotein levels in phase ii
Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers th...
June 1, 2022, 10:32 am
Blue-chip stock could soon cool from recent rally
Blue-chip name Amgen, Inc. (NASDAQ:AMGN) earlier reported its olpasiran therapy helped reduce chole...
May 31, 2022, 3:07 pm